The “Subscription Access” service option offered by BioNews Services offers content providers interested in limited or occasional content downloads 24/7 access to the BNS hub and select specific types of content to review and download.

The BNS editorial team provide daily multi-platform content, meticulously researched and fact-checked, focused not only on patients but their family members, caregivers, and health professionals who care for them. Each day, BNS content covers drug trials and approvals; research findings; issues affecting caregivers; treatment developments; FDA actions; social and cultural trends related to coping with rare diseases; and insights from patient columnists that affect patient well-being.

“Subscription Access” registrants may be interested in particular disease verticals or columnists for regular publication or stories or columns on an occasional basis.

To evaluate whether this option is compatible with your needs, we would like to highlight some links on that can accelerate the learning curve, including:

  • The home page includes content that have posted within the last 72 hours. Stories and columns are organized separately, and content dedicated to our quarterly special report topic, currently COVID-19 coverage, is highlighted.
  • Under the “About Us” link, you’ll find detailed information covering the contractual parameters for using and repurposing BNS content, as well.
  • The “Marketing Kit” link provides a full analysis of the readership and advertising opportunities that exist when effectively leveraging BNS content.
  • The “News Digest” link is your master index to all BNS content, organized by disease name and dating back a full year. In addition, links to specific disease verticals are indexed on most interior pages throughout the site.
  • Column logos are included in the downloads but not required. The title of the column and its author are required when using your own style or design formats for presentation.

For more information, [email protected] You’ll receive a reply within 24 hours.